Capital International Sarl Agios Pharmaceuticals, Inc. Transaction History

Capital International Sarl

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$33.21 - $46.54 $272,255 - $381,534	-8,198 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$33.87 - $55.93 $8,941 - $14,765	264 Added 3.33%	8,198 $287,000
Q2 2020 Aug 14, 2020	BUY	$34.45 - $53.48 $54,913 - $85,247	1,594 Added 25.14%	7,934 $424,000
Q1 2020 May 15, 2020	SELL	$31.52 - $53.81 $623,812 - $1.06 Million	-19,791 Reduced 75.74%	6,340 $225,000
Q4 2019 Feb 18, 2020	BUY	$30.08 - $50.59 $118,244 - $198,869	3,931 Added 17.71%	26,131 $1.25 Million
Q3 2019 Nov 14, 2019	SELL	$32.4 - $49.58 $249,480 - $381,766	-7,700 Reduced 25.75%	22,200 $719,000
Q1 2019 May 15, 2019	SELL	$45.92 - $67.67 $206,640 - $304,515	-4,500 Reduced 13.08%	29,900 $2.02 Million
Q3 2018 Nov 14, 2018	BUY	$71.67 - $91.95 $523,191 - $671,235	7,300 Added 26.94%	34,400 $0
Q1 2018 May 15, 2018	SELL	$59.83 - $86.53 $329,065 - $475,915	-5,500 Reduced 16.87%	27,100 $2.22 Million
Q4 2017 Feb 14, 2018	SELL	$52.12 - $72.33 $5.12 Million - $7.1 Million	-98,200 Reduced 75.08%	32,600 $1.86 Million
Q3 2017 Nov 14, 2017	BUY	$54.89 - $67.12 $7.18 Million - $8.78 Million	130,800	130,800 $8.73 Million

233

58.1M

403K

469K

Ticker AGIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,818,000
Market Cap $1.78B
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...

Get notified when there are updates to the investment portfolio of Capital International Sarl, based on Form 13F filings with the SEC.

Stay updated on Capital International Sarl with notifications on news.